What is Solventum's interest income (expense), nonoperating?

Solventum (SOLV) reported interest income (expense), nonoperating of -$62M in Q1 2026.

How has Solventum's interest income (expense), nonoperating changed year-over-year?

Solventum's interest income (expense), nonoperating increased by 40.4% year-over-year, from -$104M to -$62M.

Solventum SOLV Interest Income (Expense), Nonoperating

Interest Income (Expense), Nonoperating at other companies

Globus MedicalGMED

——

Baxter InternationalBAX

——

Medline, Inc. MDLN

——

Other financials

Income statement

See full

Revenue$2.0B-3.0%

Gross profit$1.1B-1.5%

Operating income$81.0M-46.7%

Net income$13.0M-90.5%

EPS (diluted)$0.07-91.0%

Balance sheet

See full

Cash & equivalents$561.0M+5.1%

Total debt$5.8B-26.8%

Total equity$5.0B+52.3%

Total assets$14.1B-3.0%

Cash flow

See full

Operating cash flow-$189.0M-752%

CapEx$84.0M-22.9%

Free cash flow-$273.0M-241%

Valuation

See full

Market cap$13.06B-13.9%

Enterprise value$18.29B-19.4%

P/E9.1×-30.9×

P/S1.6×-0.2×

Profitability

See full

Gross margin53.7%-0.9pp

Operating margin25.5%+15.8pp

Net margin17.3%+12.8pp

FCF margin4.6%-13.9pp

Returns & leverage

See full

Return on equity34.8%+24.1pp

Debt / equity1.2×-1.3×

Current ratio1.1×-0.1×

Where this comes from

Reported directly by Solventum in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.

The official record: Solventum’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Solventum's interest income (expense), nonoperating.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Solventum's interest income (expense), nonoperating?: Solventum (SOLV) reported interest income (expense), nonoperating of -$62M in Q1 2026.
How has Solventum's interest income (expense), nonoperating changed year-over-year?: Solventum's interest income (expense), nonoperating increased by 40.4% year-over-year, from -$104M to -$62M.